US Edition
Regor to Present Data on its Lead Obesity Candidate, RGT-075, at the 85th Scientific Sessions of American Diabetes Association (ADA)
Summary by CNHI News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Regor to Present Data on its Lead Obesity Candidate, RGT-075, at the 85th Scientific Sessions of American Diabetes Association (ADA)
CAMBRIDGE, Mass., June 13, 2025 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a global innovator of clinical-stage biotechnology, today announced that it will present results from its Phase 2a trial of RGT-075 in adults with obesity or overweight with weight-related comorbidities…
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
